Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.
Sullivan HC, Gerner-Smidt C, Nooka AK, Arthur CM, Thompson L, Mener A, Patel SR, Yee M, Fasano RM, Josephson CD, Kaufman RM, Roback JD, Lonial S, Stowell SR. Sullivan HC, et al. Among authors: lonial s. Blood. 2017 Jun 1;129(22):3033-3037. doi: 10.1182/blood-2016-11-749432. Epub 2017 Apr 3. Blood. 2017. PMID: 28373263 Free PMC article. Clinical Trial. No abstract available.
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC; SUMMIT/CREST Investigators. Lonial S, et al. Blood. 2005 Dec 1;106(12):3777-84. doi: 10.1182/blood-2005-03-1173. Epub 2005 Aug 11. Blood. 2005. PMID: 16099887 Free PMC article. Clinical Trial.
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Richardson PG, et al. Among authors: lonial s. Blood. 2007 Nov 15;110(10):3557-60. doi: 10.1182/blood-2006-08-036947. Epub 2007 Aug 9. Blood. 2007. PMID: 17690257 Free article. Clinical Trial.
Risky business in myeloma.
Lonial S. Lonial S. Blood. 2009 Jul 16;114(3):496-7. doi: 10.1182/blood-2009-04-217281. Blood. 2009. PMID: 19608754 Free article.
Supportive therapies in multiple myeloma.
Gleason C, Nooka A, Lonial S. Gleason C, et al. Among authors: lonial s. J Natl Compr Canc Netw. 2009 Oct;7(9):971-9. doi: 10.6004/jnccn.2009.0064. J Natl Compr Canc Netw. 2009. PMID: 19878640 Review.
Improving induction therapy in multiple myeloma.
Nooka A, Gleason C, Lonial S. Nooka A, et al. Among authors: lonial s. Curr Hematol Malig Rep. 2010 Jul;5(3):119-28. doi: 10.1007/s11899-010-0057-7. Curr Hematol Malig Rep. 2010. PMID: 20449692 Review.
469 results